Clinical Research Program
Geneoscopy is committed to leveraging its platform technology to assess RNA biomarkers non-invasively in stool to advance research and clinical management of gastrointestinal disease, initially in colorectal cancer. These studies are taking place in collaboration with academic and institutional leaders in the field and will allow us to offer new ways for clinicians to help prevent and diagnose disease, monitor patient health, and improve health outcomes.
CRC-PREVENT is a prospective, multi-site study that will evaluate individuals aged 45-84 who are at average risk for colorectal cancer. If successful, Geneoscopy expects data from the trial will support a premarket approval (PMA) submission to the FDA.
For Investigational Use Only. Not available for commercial sale. The performance characteristics of this product have not been established. Geneoscopy will be seeking FDA Premarket Approval for its colorectal cancer screening test following completion of CRC-PREVENT.